Atopic Dermatitis
Latest News
Shorts
1:30
Why Food Testing Often Fails for Atopic Dermatitis
a month ago
by
Renata Block, DMSc, MMS, PA-C(+1 more)
Podcasts
Continuing Medical Education
All News
Advertisement
In this episode, Renata Block, DMSc, MMS, PA-C, and Zachary Rubin, MD, discuss the overlapping worlds of allergy and dermatology—and how better cross-specialty understanding can dramatically improve patient outcomes.
Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.
Affecting up to 25% of children worldwide, pediatric AD carries a significant quality of life burden that extends to caregivers.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Eight in ten ADlong patients achieved clinical response without steroid rescue, strengthening the case for lebrikizumab as a standalone, long-term management option.
Missed the late-breaking sessions? Review our quick guide of all the need-to-know data from AAD 2026.
Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.
Renata Block, DMSc, MMS, PA-C, and Jamie Restivo, MPAS, PA-C, explore how hypochlorous acid sprays and sodium hypochlorite washes simplify AD adjunct care, improving adherence, antimicrobial control, and symptom relief.
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.
Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.
Advertisement
A combined group of ophthalmology and dermatology specialists traveled to communities in Nepal to conduct consultations, procedures, and teaching sessions, and specifically in dermatology, skin malignancy removals, trainings on biologics and JAKs, and melanoma detection demonstrations.
Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Sun, Science, and Skin: Dermatology's Biggest Spotlights This June
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5